IJCS | Volume 33, Nº4, July and August 2020

376 1. Stringhini S, Carmeli C, Jokela M, Avendaño M, McCrory C, d´Errico A, et al, Socioeconomic status, non-communicable disease risk factors, andwalking speed in older adults: multi-cohort population based study. BMJ. 2018;360:k1046. 2. GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1659-724. 3. Ecuador.Ministerio de Salud Publica del Ecuador.Anuario De Vigilancia Epidemiológica 1994 – 2016. Enfermedades Crónicas No Transmisibles. Report; 2018. 4. López-Cevallos D. Tomo I: Encuesta Nacional de Salud y Nutrición de la población ecuatoriana de cero a 59 años. ENSANUT-ECU 2012 por Freire Wilma, et al Rev Mundos Plurales. 2015;2(1):119-21. 5. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421. 6. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581-90. 7. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-81. 8. Sando KR, Knight M. Nonstatin therapies for management of dyslipidemia: a review. Clin Ther. 2015;37(10):2153-79. 9. Stone NJ, Robinson JG, Lichtenstein AH, Merz NB, Blum CB, Eckel RH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Circulation. 2014;129(25 suppl 2):S1-S45. 10. National Institutes of Health. National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatmentof High Blood Cholesterol inAdults (Adult Treatment Panel III). NIH: Maryland; 2002. (Final Report: 02-5215). 11. Meaney E, Vela A, Ramos A, Alemao E, Yin D. Cumplimiento de las metas con reductores del colesterol en pacientes mexicanos. El estudio COMETA México. Gac Med Mex. 2004;140(5):493-501. 12. Estrella A, Hernandez I, Salazar J, Duarte Y, Teran E. ATPIII goals accomplishment with the different treatments for dyslipidemia at the hospital centers in Quito and Guayaquil. Rev Fac Cien Quim. 2016;ed esp:35-40. 13. Stacy TA, Egger A. Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high- volume prescribers of lipid-modifying drugs. J Manag Care Pharm. 2006;12(9):745-51. 14. Chung PW, Yoon BW, Lee YB, Shin BS, KimHY, Park JH, et al. Medication adherence of statin users after acute ischemic stroke. Eur Neurol. 2018;80(1-2):106-14. 15. Lansberg P, Lee A, Lee ZV, Subramaniam K, Setia S. Nonadherence to statins: individualized intervention strategies outside the pill box. Vasc Health Risk Manag. 2018 May 24;14:91-102. 16. A Vonbank A, Drexel H, Agewall S, Lewis BS, Dopheide JF, Kjeldsen K, et al. Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review. Eur Heart J Cardiovasc Pharmacother. 2018;4(4):230-6. 17. Hernandez I, Sarmiento N, Gonzalez I, Galarza S, Bastida A, Teran S, et al. Adherence to treatment in outpatient patients of health centers in Quito. Rev Metro Ciencia. 2018;26(1);7-11. References Ethics approval and consent to participate This study was approved by the Ethics Committee of the USFQ under the protocol number 2015-044IN. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study. Hernández et al. Dyslipidemia treatment in Ecuadorian population Int J Cardiovasc Sci. 2020; 33(4):371-376 Original Article This is an open-access article distributed under the terms of the Creative Commons Attribution License